Dr. Kelly K. Bree, MD

Dr. Bree practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Bree's NPI, 1023428802, was assigned on May 2, 2014. Dr. Bree graduated from George Washington University School of Medicine and Health Sciences in 2014. Dr. Bree holds Texas license S6139.

Dr. Bree's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Bree's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bree practices. Vendor and product names are available with a free account.

Urology is Dr. Bree's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Bree is board certified in urology by the American Board of Urology. Dmand AI has Dr. Bree's licenses on file in 2 states: Texas and California.

Dmand AI lists bladder removal, kidney cysts, kidney removal surgery, urinary endoscopy and urine flow blockage among the conditions Dr. Bree treats.

CMS data shows 341 Medicare services from Dr. Bree across 8 procedure codes in 2024, for 227 Medicare patients. Medicare paid $35,184 for them. Every service was in an office.

CMS counts 227 Medicare patients who saw Dr. Bree in 2024. The largest group is 65 to 74, with 133 patients. 75% of them have cancer, and 75% have high cholesterol. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bree's median patient age at 75, with 23% women.

In 2024, Dr. Bree wrote 131 Medicare Part D claims for 57 patients. 95% of them were for generic drugs. CMS names the drug for 80 of them, across 3 drugs with 11 or more claims each, at $966 in total drug cost. In 2023, CMS named 49 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Bree for performance year 2024, reported as part of a group. Dr. Bree accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bree as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Removal of the uterus: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 43 papers to Dr. Bree, published from 2019 to 2025. 2021 was the busiest year, with 14. The most frequent topics are Urinary Bladder Neoplasms, Cystectomy and Neoplasm Invasiveness. Dr. Bree has published most often in J Urol. Dr. Bree's most frequent co-authors are Ashish M. Kamat, MD, Neema Navai, MD and Colin P. Dinney, MD.

Dmand AI links Dr. Bree to 2 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell and Urinary Bladder Neoplasms.

CMS Open Payments shows 17 general payments to Dr. Bree from 7 drug and device companies from 2018 to 2025. Travel and lodging make up the largest share, 53% of the total. Intuitive Surgical, Inc. paid the most, $1,052.

Dmand AI lists 1 award for Dr. Bree, most recently Physicians Referral Service Top Performer (Top 10th percentile nationally) in 2023.

Dr. Bree graduated from George Washington University School of Medicine and Health Sciences in 2014.

Dr. Bree is in network with 5 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 4. Check the plan with the practice before a visit.